Bacterfin (Clarithromycin) is generally used to help manage a wide variety of bacterial infections.

What Bacterfin Treats: Main Uses and Benefits

Bacterfin is generally used in conditions marked by heightened, acute symptoms stemming from bacterial infections. This medication is commonly applied in clinical settings for pneumonia, bronchitis, sinusitis, and otitis media, as well as uncomplicated skin infections and for addressing the bacterial cause of peptic ulcer disease. It helps address groups of symptoms that may appear suddenly, such as fever, persistent cough, and localized pain. The medication is also relevant when supportive symptom management is appropriate for immunocompromised individuals or those with a documented allergy to penicillin-class antibiotics.

This therapeutic application provides support that helps ease the overall symptom load and contributes to improved comfort during difficult episodes.

“It plays a role in managing symptoms by assisting with the management of discomfort related to healing.”

Quick Fact: Support for Respiratory Discomfort Bacterfin is commonly used to address symptoms related to heightened physiological activity in the respiratory tract, such as acute cough and chest discomfort, supporting the patient during symptomatic periods.

Eligibility Map: Who can and cannot use Bacterfin — official regulatory information

Eligibility Scope	Status/Rules (as stated in regulatory documents)
Populations for whom use is contraindicated	Absolute prohibition for patients with hypersensitivity to clarithromycin or other macrolide antibiotics; a history of cholestatic jaundice or hepatic dysfunction from prior clarithromycin use; or a history of QT prolongation or ventricular cardiac arrhythmia. Use is also contraindicated in patients taking specific medications, including Lovastatin, Simvastatin, Ergotamine, Dihydroergotamine, Cisapride, and Pimozide.
Age-related eligibility rules	Approved for adults and adolescents (12 years and older). Safety and efficacy are not established for infants under six months of age. Children under 12 years must use the oral suspension form; tablets are not suitable.
Condition-specific eligibility rules	Patients with severe renal impairment (Creatinine Clearance < 30 mL/min) require a mandated 50% reduction in dosage. Caution is advised for patients with pre-existing cardiac conditions, uncorrected low potassium or magnesium levels, or isolated impaired hepatic function. The medicine is contraindicated in patients with severe hepatic failure combined with renal impairment.
Pregnancy and lactation eligibility	Use during pregnancy is not recommended unless the benefit is determined to outweigh the risk. Safety is not established during breastfeeding; discontinuation of nursing is advised.

---

The official regulatory documents establish strict eligibility based on absolute prohibitions, particularly concerning cardiac risk factors and drug interactions, which dictate that certain populations must not use the medicine. For other groups, eligibility is conditional, requiring mandatory dose adjustments for patients with severe renal impairment and caution for the elderly or those with underlying cardiac issues, defining precise population restrictions.

Interactions with other medicines and products

Bacterfin (sulfamethoxazole/trimethoprim) can interact with several other medicinal products, requiring careful medical supervision, dose adjustments, or avoidance of the combination. Certain combinations are explicitly contraindicated, such as simultaneous use with the antiarrhythmic medication Dofetilide.

Key Interactions

The product can significantly alter the effects of medications like the blood thinner Warfarin, potentially increasing the risk of bleeding; close monitoring of blood clotting time (INR) is necessary if they are used together. Similarly, it may raise the blood levels of the anti-seizure medication Phenytoin and the heart medication Digoxin, particularly in elderly patients, necessitating therapeutic drug monitoring.

Interacting Drug Classes

Bacterfin can potentiate the effects of certain oral diabetes medications (hypoglycemic agents) like glyburide and metformin, which may lead to low blood sugar and require frequent glucose monitoring. Other drugs that may interact include the immunosuppressant Cyclosporine, the antiretroviral Zidovudine, and certain drugs that the kidney eliminates using the OCT2 transporter (such as Amantadine and Memantine).

Important Precautions

Avoidance of this product is recommended when using adjunctive Leucovorin for Pneumocystis jirovecii pneumonia due to associated risks. Patients should always inform their healthcare providers about all prescription, over-the-counter, and herbal products they are using before starting or stopping Bacterfin.

How Bacterfin Works

Bacterfin, containing Clarithromycin, exerts its primary action as an inhibitor of bacterial growth. The drug specifically and reversibly binds to the 23S ribosomal RNA (rRNA) component of the bacteria’s 50S ribosomal subunit . This interaction physically blocks the ribosomal exit tunnel, immediately halting the process of protein synthesis and preventing the pathogen from proliferating. This sustained arrest of bacterial growth represents the core physiological consequence of the mechanism, resulting in a low or non-proliferating pathogen load.

Beyond this direct antibacterial effect, Clarithromycin engages a secondary mechanistic domain: the modulation of host physiological pathways. The drug can reduce the production of pro-inflammatory mediators (like cytokines) and influence the signaling cascades that regulate the expression of mucin genes in epithelial cells. This non-antibacterial effect results in the modulation of signaling dynamics within the targeted tissues and produces a reduction in local inflammatory mediators.

However, the drug’s mechanism is physiologically constrained by the development of bacterial resistance. Resistance arises when bacteria chemically modify the target site (23S rRNA) or when they overexpress efflux pumps that actively expel the drug from the cell. These counter-mechanisms prevent the drug from achieving the necessary ribosomal blockade, overriding the inhibitory action and compromising the intended physiological effect.

The administration of Bacterfin (a combination product of sulfamethoxazole and trimethoprim) should adhere to the dosing and procedural instructions provided by a healthcare professional.

Administration Routes and Dosing

This medicine is available for oral intake (as a tablet or suspension) or by intravenous (IV) infusion.

Adults: The typical oral regimen for most conditions is one Double Strength (DS) tablet (800 mg sulfamethoxazole and 160 mg trimethoprim) every 12 hours. The total course duration is usually 5 to 14 days, as specified by the prescribing authority for the condition being addressed.

Pediatric Patients (Ages 2 months and older): The required dose is determined by body weight, calculated as 40 mg of sulfamethoxazole and 8 mg of trimethoprim per kilogram of body weight per 24 hours, divided into two doses every 12 hours.

Preparation and Procedural Rules

• Oral Administration: Tablets and suspensions may be taken with or without food. Oral forms should be consumed with a full glass of water to prevent certain unwanted effects. If using the suspension, the bottle must be shaken well before each dose measurement.
• Intravenous Infusion: The IV solution must be diluted in 5% Dextrose in Water or other compatible solutions prior to administration. The final mixture is administered as a slow intravenous infusion over a period of 60 to 90 minutes; rapid infusion or bolus injection must be avoided.

Special Dosing Conditions

For patients with confirmed renal impairment, specifically those with a creatinine clearance (CrCl) between 15 mL/min and 30 mL/min, the dosage is reduced by 50%. If a regular dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent taking two doses too close together.

Research Evidence / Overview of Studies for Bacterfin

The clinical understanding of Bacterfin (Clarithromycin) is built upon official clinical research and scientific reviews referenced by regulatory bodies. The research primarily consists of Randomized Controlled Trials (RCTs), where the medicine is compared against other active comparator agents or, less commonly, against an inactive substance, alongside large-scale observational studies. The following summary reflects the patterns and limitations described in the research, without providing medical advice or specific usage instructions.

---

Evidence for Use in Respiratory Tract Infections

Research exploring the use of Bacterfin was studied for upper and lower respiratory conditions. Studies for upper respiratory conditions were primarily short-term RCTs that monitored two main outcomes: bacteriological eradication and clinical improvement in signs and symptoms. For lower respiratory infections, the evidence base is also extensive, including studies that monitored high-level outcomes such as hospitalization rates and all-cause mortality in severe patient groups. The evidence level for this area is generally classified as High in regulatory reviews.

---

Evidence for Eradication of H. pylori

Bacterfin was studied for its role as one component of multi-drug regimens used to eliminate Helicobacter pylori. Research consists of RCTs that measured the critical outcome of eradication status. Findings describe patterns observed in the studies that tracked bacterial clearance, but the reported outcomes are often difficult to interpret in isolation because Bacterfin was observed in combination with other medicines. The consistency of evidence is challenged by increasing regional resistance to Clarithromycin.

---

Long-Term Studies and Extended Follow-up

Extended follow-up studies and large-scale retrospective observational studies have explored patient outcomes far beyond the treatment period, sometimes spanning several years. These studies described observations of specific patterns, including an association with increased cardiovascular mortality at follow-up intervals several years after a short treatment course. However, findings were mixed between different observational studies, and a clear biological explanation for this long-term observation is not fully established. Therefore, certainty remains low in the interpretation of these long-term data.

---

Research in Special Patient Populations

Bacterfin was evaluated in special patient populations, including pediatric patients (children) for indications such as respiratory and skin infections, to explore whether research findings apply to these age groups. Furthermore, the medicine was studied for use in immunocompromised patients (e.g., HIV-positive adults) for the prevention or treatment of Mycobacterium Avium Complex (MAC) infection. For MAC infection, Bacterfin was observed in combination with other drugs, and studies tracked outcomes over long-term follow-up periods. Data for certain groups remain insufficient.

---

Where the Research Remains Uncertain

While a large volume of research exists, some limitations remain. The findings reported in trials may be challenged by increasing regional resistance to macrolide antibiotics, leading to inconsistent treatment patterns globally. In the case of H. pylori and MAC, the isolated contribution of Bacterfin is difficult to fully assess because it is predominantly studied as part of a combination regimen. Research provides context but not individual predictions about how any patient will respond.

Key Studies & References

1. U.S. National Library of Medicine: DailyMed - Clarithromycin Tablets, Oral Suspension, and Extended-Release Tablets

Common questions about Bacterfin (FAQ)

Q: Is Bacterfin considered a broad-spectrum antibiotic?

Official information indicates that Bacterfin is approved for treating infections caused by designated susceptible organisms. While it is shown to be active in laboratory testing against a variety of gram-positive and gram-negative bacteria, the medication is prescribed for specific bacterial conditions rather than being universally labeled as a broad-spectrum drug.

Q: How quickly does Bacterfin usually start working after the first dose?

According to official drug information, peak concentrations of Bacterfin in the bloodstream are typically reached about 2 to 3 hours after the oral medication is administered. It generally takes about three days of regular dosing to reach a consistent, steady-state level of the drug in the body.

Q: Does Bacterfin treat viral infections like the common cold?

No. Official regulatory documents classify Bacterfin as an antibacterial drug. It is intended only for treating or preventing infections that are proven or strongly suspected to be caused by bacteria; it is not effective against viruses, such as those that cause the common cold or flu.

Q: Does alcohol interact negatively with Bacterfin?

Official product labeling for Bacterfin does not list a specific contraindication or negative interaction between the medication and alcohol.

Q: How long does the effect of Bacterfin last in the body?

The time it takes for half of the drug to be eliminated from the body, known as the elimination half-life, is documented to range from approximately 3 to 7 hours, depending on the administered dosage.

Q: Will Bacterfin affect the effectiveness of my birth control pill?

Regulatory information indicates that Bacterfin may potentially alter the levels of certain components in oral contraceptives. This change may potentially lead to changes in effectiveness or an increase in adverse effects, and is an important consideration.

Q: Why do people sometimes get a yeast infection after taking Bacterfin?

Official warnings note that the use of antibiotics like Bacterfin can sometimes lead to an overgrowth of non-susceptible organisms, which includes fungi. This overgrowth is a common mechanism associated with the potential development of secondary fungal infections, such as a yeast infection.

Q: Are headaches a common side effect of Bacterfin?

Yes, headaches are listed in regulatory documents as one of the most frequently reported adverse reactions experienced by patients in clinical trials for Bacterfin.

Q: Can people with liver problems use Bacterfin?

According to official guidelines, Bacterfin is prohibited for patients with severe liver failure combined with kidney impairment. Caution is advised for patients presenting with isolated impaired liver function.

Q: Why is it important to finish the whole course of Bacterfin?

Official usage instructions emphasize that it is important that the full prescribed duration of Bacterfin is administered. This measure is essential to help reduce the development of drug-resistant bacteria and maintain the intended effectiveness of this and other antibacterial drugs.

Q: What evidence supports the use of Bacterfin for respiratory infections?

Bacterfin is officially approved for treating a range of respiratory infections, including conditions like community-acquired pneumonia. This approval is based on clinical studies demonstrating its efficacy in treating these specific bacterial conditions.

Q: Can Bacterfin be prescribed for urinary tract infections (UTIs)?

No. According to the official regulatory indications for use, urinary tract infections (UTIs) are not listed as an approved indication for Bacterfin.

Q: Can children be prescribed Bacterfin?

Official information confirms that the safety and effectiveness of Bacterfin have been established for pediatric patients who are 6 months of age and older for specific approved infections.

Q: What is the main difference between Bacterfin and Amoxicillin?

Official pharmacological sources note that Bacterfin is a macrolide antibiotic that works by stopping bacteria from making necessary proteins. Amoxicillin, by contrast, is a penicillin-class antibiotic that works by breaking down the bacteria's cell wall. These different mechanisms of action are documented in regulatory information.

Q: Is it normal to feel tired or dizzy when starting Bacterfin?

Official adverse reaction lists mention dizziness and insomnia as reported effects. Such effects may impact cognitive functions, potentially presenting as general feelings of being unwell or tired. If these occur, caution is advised.

Q: What happens if I miss a dose of Bacterfin?

Official instructions describe the procedure for a missed dose: if a dose is forgotten, it can be administered when remembered. However, if the next scheduled dose is due shortly, the missed dose is skipped. The guidance is to avoid administering two doses too closely together.

Q: Do I need to take Bacterfin with food, or can I take it on an empty stomach?

Official dosage instructions state that both the immediate-release tablets and the oral suspension forms of Bacterfin can be administered without regard to meals. The medication can be taken with or without food.

Q: Is it safe to use Bacterfin if I have a known kidney issue?

According to regulatory guidelines, Bacterfin is used conditionally in patients with kidney issues. For patients presenting with severe kidney impairment, a mandated dosage adjustment is required.

Q: Does Bacterfin interact with common pain relievers like Ibuprofen?

The official product labeling lists interactions with several major drugs, but a specific interaction with common pain relievers like Ibuprofen is not mentioned. It is important that healthcare providers are informed about all medications being taken.

Q: Can taking Bacterfin affect my ability to drive or operate machinery?

Official safety information indicates that adverse reactions such as dizziness, vertigo (a spinning sensation), or confusion may occur. These effects could potentially impair the ability to safely drive or operate machinery.

Q: Are there any herbal supplements that should not be taken with Bacterfin?

Bacterfin is known to interact with a wide variety of medications. Regulatory guidance suggests that patients should ensure their healthcare providers are informed about all herbal products and supplements being used before starting treatment.

Q: Is the liquid form of Bacterfin as effective as the tablet form?

Both the oral suspension (liquid) and the tablet forms of Bacterfin are officially approved for administration. The forms are generally chosen based on the patient's age and clinical need, and official studies confirm both forms provide comparable drug absorption into the body.

Q: What distinguishes Bacterfin from Penicillin-based antibiotics?

Bacterfin (a macrolide) stops bacteria by blocking protein production. Penicillin-based antibiotics use a different approach by disrupting the building of the bacterial cell wall. This fundamental difference in the mechanism of action is detailed in regulatory pharmacology documents.

Q: Does Bacterfin cause insomnia or restlessness?

Yes, official adverse event lists specify that insomnia, or difficulty sleeping, is a commonly reported side effect associated with the use of Bacterfin.

Q: What is the mechanism by which Bacterfin kills bacteria?

According to the official mechanism of action, Bacterfin works by binding to a specific part of the bacteria's ribosome. This binding action inhibits (stops) the bacteria from being able to synthesize proteins, which prevents the microorganism from growing or multiplying.

Q: Is it normal to have a metallic taste while taking Bacterfin?

Yes, regulatory documents list dysgeusia, which is described as an unusual, altered, or unpleasant taste sensation, as one of the most frequently reported adverse reactions to Bacterfin.

Official Storage and Disposal Requirements

This information reflects the mandatory requirements set forth in official regulatory labeling and governmental guidelines.

Storage Scope	Requirement
Temperature and Environment	Store the medication at room temperature. Keep away from excess heat and moisture.
Container Security	Keep the medication in the original container, tightly closed, and strictly out of the reach of children.
Stability	Stability is maintained until the official expiration date when stored according to labeled instructions.

Disposal Instructions

To dispose of unused or expired Bacterfin, the preferred method is to utilize a community drug take-back program. If this option is unavailable and the product is not on the government's flush list, it must be prepared for household trash disposal. This preparation involves removing the product from its container, mixing it with an undesirable substance (such as used coffee grounds or dirt), placing the mixture in a sealed bag or container, and then discarding it in the trash. The product must not be flushed down a toilet or washed down a sink.